Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, U6 small nuclear 209, pseudogene (RNU6-209P)** is a non-coding RNA gene classified as a processed pseudogene in humans. This gene is a derivative of the functional U6 small nuclear RNA (snRNA) gene, but due to mutations or lack of required regulatory elements, it does not produce a functional RNA product. U6 snRNAs are core RNA components of the spliceosome and play a central role in pre-mRNA splicing, but RNU6-209P, as a pseudogene, is not functionally involved in this process[1][2][3]. Pseudogenes like RNU6-209P can arise from retrotransposition events or gene duplication followed by disabling mutations, and they are generally considered non-functional. There is no evidence supporting a role for RNU6-209P as a therapeutic target, nor any associations with disease, drug interactions, or biomarker use[1][3]. **Key points:** - This entry refers to a *pseudogene*, not an active protein, RNA, or drug target[1][3]. - It is *not* considered a therapeutic or diagnostic target. - The entry is “incorrect” as a drug target due to its pseudogene status, lack of biological function, and non-involvement in disease pathways. **Supporting notes:** - The canonical U6 snRNA (not the pseudogene) is highly conserved and essential for spliceosome function, but pseudogenes like RNU6-209P are usually “dead copies” and do not contribute to cellular biology in a meaningful way in current research[2][3]. - No drugs, biomarkers, mechanisms of action, or safety issues are associated with this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 209, pseudogene (RNU6-209P).